Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NYSE:BHC NASDAQ:KYTX NASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.81-6.0%$14.27$8.50▼$20.76$2.35B2.161.78 million shs1.52 million shsBHCBausch Health Cos$5.78+0.8%$5.48$4.41▼$8.69$2.14B0.421.77 million shs1.25 million shsKYTXKyverna Therapeutics$9.35+0.5%$8.82$2.05▼$13.67$562.93M2.051.25 million shs458,952 shsOCULOcular Therapeutix$9.65-0.3%$9.08$6.23▼$16.44$2.12B0.932.92 million shs2.10 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+4.18%-1.01%-6.85%+66.84%BHCBausch Health Cos0.00%0.00%+7.31%-2.80%+21.68%KYTXKyverna Therapeutics0.00%+5.68%+0.87%+17.28%+360.40%OCULOcular Therapeutix0.00%+3.31%+14.96%+5.68%+37.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$13.81-6.0%$14.27$8.50▼$20.76$2.35B2.161.78 million shs1.52 million shsBHCBausch Health Cos$5.78+0.8%$5.48$4.41▼$8.69$2.14B0.421.77 million shs1.25 million shsKYTXKyverna Therapeutics$9.35+0.5%$8.82$2.05▼$13.67$562.93M2.051.25 million shs458,952 shsOCULOcular Therapeutix$9.65-0.3%$9.08$6.23▼$16.44$2.12B0.932.92 million shs2.10 million shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies0.00%+4.18%-1.01%-6.85%+66.84%BHCBausch Health Cos0.00%0.00%+7.31%-2.80%+21.68%KYTXKyverna Therapeutics0.00%+5.68%+0.87%+17.28%+360.40%OCULOcular Therapeutix0.00%+3.31%+14.96%+5.68%+37.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.63Moderate Buy$20.0044.82% UpsideBHCBausch Health Cos 1.80Reduce$8.0038.53% UpsideKYTXKyverna Therapeutics 2.60Moderate Buy$28.67206.60% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78146.40% UpsideCurrent Analyst Ratings BreakdownLatest KYTX, ADPT, BHC, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ADPTAdaptive Biotechnologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $21.005/6/2026ADPTAdaptive Biotechnologies JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $19.005/6/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.005/6/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/23/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ADPTAdaptive Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M7.98N/AN/A$1.40 per share9.86BHCBausch Health Cos$10.27B0.21$7.31 per share0.79($2.89) per share-2.00KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/AOCULOcular Therapeutix$51.95M40.67N/AN/A$2.66 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%N/ABHCBausch Health Cos$157M-$3.24N/A1.51N/A-11.47%-2,922.77%5.63%N/AKYTXKyverna Therapeutics-$161.31M-$3.65N/AN/AN/AN/A-81.47%-66.70%5/12/2026 (Estimated)OCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%N/ALatest KYTX, ADPT, BHC, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75N/AN/AN/AN/AN/A5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion3/26/2026Q4 2025KYTXKyverna Therapeutics-$0.80-$0.80N/A-$0.80N/AN/A2/18/2026Q4 2025BHCBausch Health Cos$1.21$1.08-$0.13-$0.30$2.71 billion$2.78 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.23BHCBausch Health Cos54.681.321.08KYTXKyverna Therapeutics0.117.757.75OCULOcular Therapeutix0.1214.8115.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%BHCBausch Health Cos78.65%KYTXKyverna Therapeutics18.08%OCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%BHCBausch Health Cos20.67%KYTXKyverna Therapeutics17.60%OCULOcular Therapeutix2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableBHCBausch Health Cos20,300373.81 million296.54 millionOptionableKYTXKyverna Therapeutics9660.53 million49.88 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionableKYTX, ADPT, BHC, and OCUL HeadlinesRecent News About These CompaniesOcular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8 at 4:05 PM | globenewswire.comOcular: SOL-1 Success Is Real, But Adoption Risks Keep Me At HoldMay 8 at 9:46 AM | seekingalpha.comOcular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation DivergeMay 8 at 9:46 AM | finance.yahoo.comHC Wainwright Has Negative Outlook for OCUL Q2 EarningsMay 8 at 7:36 AM | marketbeat.comBrokers Set Expectations for OCUL FY2027 EarningsMay 7 at 8:34 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Needham & Company LLCMay 7 at 8:19 AM | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Given Outperform Rating at Royal Bank Of CanadaMay 7 at 4:25 AM | americanbankingnews.comOcular Therapeutix (OCUL) Gets a Buy from H.C. WainwrightMay 6 at 10:12 PM | theglobeandmail.comWhy Ocular Therapeutix (OCUL) Stock Is NosedivingMay 6 at 10:12 PM | theglobeandmail.comAssessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile ReturnsMay 6 at 10:12 PM | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of CanadaMay 6 at 12:35 PM | marketbeat.comOcular Therapeutix outlines SOL-R top line data in Q1 2027 while advancing AXPAXLI NDA planMay 5, 2026 | msn.comOcular Therapeutix Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comOcular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comOcular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPSMay 5, 2026 | marketbeat.comOcular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesMay 5, 2026 | zacks.comOcular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To ExpectMay 5, 2026 | finance.yahoo.comOcular Therapeutix: Q1 Earnings SnapshotMay 5, 2026 | chron.comOcular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 EarningsMay 5, 2026 | finance.yahoo.comOcular Therapeutix™ Reports First Quarter 2026 Financial Results and Business HighlightsMay 5, 2026 | globenewswire.comOcular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving Average - Here's What HappenedMay 5, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKYTX, ADPT, BHC, and OCUL Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$13.81 -0.88 (-5.99%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$13.88 +0.06 (+0.47%) As of 05/8/2026 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Bausch Health Cos NYSE:BHC$5.78 +0.05 (+0.79%) Closing price 05/8/2026 03:58 PM EasternExtended Trading$5.76 -0.01 (-0.23%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Kyverna Therapeutics NASDAQ:KYTX$9.35 +0.05 (+0.54%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.35 0.00 (0.00%) As of 05/8/2026 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Ocular Therapeutix NASDAQ:OCUL$9.65 -0.03 (-0.31%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$9.44 -0.22 (-2.23%) As of 05/8/2026 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
